GSK asthma drug Nucala's long-term study supports safety profile
0
(Reuters) - GlaxoSmithKline Plc said on Saturday its asthma drug, Nucala, which is already approved in the United States and Europe, showed a similar safety profile in a long-term study compared with previous studies.